The mechanisms by which the brain's immune cells destroy retinal neurons have been nearly impossible to study in living humans — until now. A new laboratory platform built entirely from human stem cells may finally give researchers a window into glaucoma and other optic neuropathies at the cellular level, potentially reshaping how inflammatory retinal diseases are modeled and treated.
Published in PNAS, this work introduces a triculture system derived from human pluripotent stem cells, combining three distinct cell types: microglia (the retina's resident immune cells), retinal ganglion cells (the neurons whose death causes irreversible vision loss in glaucoma), and a third supporting cell population. By recreating a physiologically relevant human microenvironment in vitro, the team was able to observe how activated microglia directly regulate — and in inflammatory states, damage — retinal ganglion cell survival. The platform allowed researchers to manipulate microglial activation states and measure downstream effects on neuronal integrity with a specificity that animal models have historically failed to provide.
This represents a meaningful methodological advance in an area long hampered by the poor translatability of rodent retinal models to human disease. Microglia behave differently across species in both baseline activity and inflammatory response, making human-derived platforms like this one scientifically valuable. The triculture design addresses a persistent criticism of simpler co-culture systems — that bilateral interactions miss the multicellular crosstalk that defines actual tissue microenvironments. That said, even sophisticated in vitro platforms omit vascular input, systemic immune signaling, and the mechanical pressures relevant to glaucoma. This remains a discovery and mechanistic tool, not a disease model in the complete sense. Still, for a field where human tissue access is extremely limited and patient-derived retinal organoids are technically demanding, this platform could become a widely adopted screening tool for anti-neuroinflammatory compounds targeting optic neuropathy.